Malignant Melanoma of The Skin - Still A Medical Conundrum?

Similar documents
Epidemiology DATA AND METHODS

Could sun exposure improve melanoma survival?

Springer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone

Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure

Title: Malignant melanoma arising from a perianal fistula and harbouring a BRAF gene mutation: a case report

Which melanoma patient carries a BRAF-mutation? A comparison of predictive models

Rare melanoma: Are the options improving? Dr Neil Steven Consultant in Medical Oncology University Hospital Birmingham University of Birmingham

Racial differences in six major subtypes of melanoma: descriptive epidemiology

Living Beyond Cancer Skin Cancer Detection and Prevention

Cutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.

Integrating Fluorescence in situ Hybridization and Genomic Array Results into the Diagnostic Workup of Melanoma

Distinct Sets of Genetic Alterations in Melanoma

STUDY. Sensitivity of Fluorescence In Situ Hybridization for Melanoma Diagnosis Using RREB1, MYB, Cep6, and 11q13 Probes in Melanoma Subtypes

Clinical characteristics

An Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center

Cover Page. The handle holds various files of this Leiden University dissertation.

Know who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated

They can develop anywhere on the skin and also inside the mouth. They can develop in normal skin or where there is an existing skin mole.

A View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.

Table Case control studies of combined estrogen progestogen contraceptives and malignant melanoma

Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment

SCENIHR Public Hearing Luxemburg Roland Laurent Swedish Tanning Association

Malignant Melanoma Early Stage. A guide for patients

Corporate Medical Policy Genetic Testing for Cutaneous Malignant Melanoma

Dermatopathology. Dr. Rafael Botella Estrada. Hospital La Fe de Valencia

Know who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated

Ethnic disparities in melanoma diagnosis and survival

Contrast with Australian Guidelines A/Pr Pascale Guitera,

Using Cancer Registry Data to Estimate the Percentage of Melanomas Attributable to UV Exposure

Bersagli molecolari nel melanoma

Frequency of BRAF Mutation and Clinical Relevance for Primary Melanomas

Sun exposure and indoor tanning and skin cancer

Melanoma Among Blacks in the United States MaryBeth Freeman, MPH ORISE Fellow

Malignant tumors of melanocytes: Part 1. Deba P Sarma, MD., Omaha

12. Malignant Melanoma of Skin

Melanoma 6/2/2011. Classification and Prognosis. Melanoma Statistics. American Cancer Society

Prevalence of Exon 15 BRAF Mutations in Primary Melanoma of the Superficial Spreading, Nodular, Acral, and Lentigo Maligna Subtypes

Malignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha

Best Practices in the Treatment and Management of Metastatic Melanoma. Melanoma

A factor which brings about a mutation is called a mutagen. Any agent that causes cancer is called a carcinogen and is described as carcinogenic.

Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Patricia Chevez-Barrrios AAOOP-USCAP /12/2016

Predisposition of Melanoma

Dermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.

Disclosures. I have no conflicts of interest to disclose

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Melanoma Epidemiology and Prevention

MELANOCYTIC LESIONS: EFFECTIVE MANAGEMENT IN PRIMARY CARE: Part 2

The European Commission's non-food Scientific Committees DG SANTE Country Knowledge and Scientific Committee Unit

Dermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial

Corporate Medical Policy

Molecular Aspects of Melanocytic Neoplasia. Iwei Yeh MD, PhD University of California, San Francisco

DR. RAMESH U2 L4 MITOSIS AND CANCER

Epidemiology. Objectives 8/28/2017

Identifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018

Cutaneous malignant melanoma (CMM) is a major

SUBUNGUAL MALIGNANT MELANOMA ON THE RIGHT INDEX IN A DENTIST AFTER PROLONGED OCCUPATIONAL EXPOSURE TO X-RAYS

Tanning Beds, Sunlamps, and Risk of Cutaneous Malignant Melanoma

Syddansk Universitet. Melanomas of the vulva and vagina. Skovsted, Sasia; Nielsen, Karsten; Blaakær, Jan. Published in: Danish Medical Journal

Histopathology of Melanoma

Index. Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035

IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY

Prevention. Skin cancer is the most common cancer in the. The Science of. by Laura Brockway-Lunardi, Ph.D.

Update on Genetic Testing for Melanoma

Protocol applies to melanoma of cutaneous surfaces only.

Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology

David B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma

Derm quiz. Go to this link: goo.gl/forms/kchrhmtzl3vfnlv52. bit.ly/2a8asoy. Scan the QR code with your phone

Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study

Chapter 2 Melanoma Pathogenesis

Professor Peter Soyer. Academic Dermatologist Brisbane, Australia

MC1R Variants Increase Risk of Melanomas Harboring BRAF Mutations

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Melanoma. Kaushik Mukherjee MD A. Scott Pearson MD

Finding Melanoma. Is not easy!

Dr. Brent Doolan, BSc MBBS MPH

Skin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1

Learning Objectives. Tanning. The Skin. Classic Features. Sun Reactive Skin Type Classification. Skin Cancers: Preventing, Screening and Treating

Although melanoma affects individuals from all ethnic

Int J Clin Exp Pathol 2015;8(8): /ISSN: /IJCEP

Black is the New Black or How I learned to stop worrying and love melanoma (with apologies to Dr. Strangelove)

HEALTH EFFECTS Biology Dr. Rüdiger Greinert Head of Dept. Mol. Cellbiology Skin Cancer Center Buxtehude/Elbeclinics Buxtehude

Clinical aspects of molecular profiles in metastatic malignant melanoma

ORIGINAL ARTICLE. Malignant melanoma in a Nigerian tertiary hospital. Chiemelu D EMEGOAKOR. Chinedu C OKOLI Odili OKOYE DISCLOSURES: NONE

Does Sunscreen Use Decrease the Incidence of Primary. Cutaneous Melanoma in Caucasians: A Systematic Review

Melanocytic Tumours. Molecular Biology 02/06/2015. Cutaneous Melanocytic Tumours Introduction. Thomas Brenn. Intermediate Malignancy

The prevention, diagnosis, referral and management of melanoma of the skin: concise guidelines

Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care

CUTANEOUS MALIGNANT MELANOMA BODY SITE, SUN EXPOSURE, GENETIC FACTORS AND PROGNOSIS

MOLECULAR ANALYSIS OF A SERIES OF ACRAL MELANOMAS IN SINGAPORE

Laboratory for Quantitative Medicine Technical Report #2 April 10, Equation Parameters

STUDY. Incidence and Survival Patterns in the United States,

Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin?

Disclosures. Melanoma and Non melanoma Skin Cancer: What You Need to Know. I have no conflicts of interest to disclose

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Pathology Research and Practice

PIGMENT CELL & MELANOMA Research

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden MUTATIONS AND MOLECULAR SIGNATURES IN HUMAN MELANOMA.

Transcription:

SCENIHR Public hearing on the Preliminary Opinion: 'Biological effects of ultraviolet radiation relevant to health with particular reference to sunbeds for cosmetic purposes. Luxembourg, April 12 th, 2016 Malignant Melanoma of The Skin - Still A Medical Conundrum? Alexander Wunsch, Physician Medical Light Consulting Heidelberg, Germany

Key Message Epidemiologic studies cited in the SCENIHR Opinion were not adjusted for some relevant host factors and confounding factors

Outline Estrogen as a confounding factor Other confounding factors Heterogeneity of melanoma as a host factor

CMM is influenced by estrogenic stimulation Oral contraceptive preparations (OCP) Hormone replacement therapies (HRT)

Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study Koomen E. R., Joosse A., Herings R. M., Casparie M. K., Guchelaar H. J. and Nijsten T. Ann Oncol 20(2):358-64 (2009) RESULTS: In total, 778 cases and 4072 controls were included. CM risk was significantly associated with estrogen use (>or=0.5 year; adjusted OR = 1.42, 95% CI 1.19-1.69). This effect was cumulative dose dependent (P trend < 0.001). CM risk was also significantly associated with the use of HRT (>or=0.5 year: OR = 2.08; 95% CI 1.37-3.14) and OC (>or=0.5 year: OR = 1.28; 95% CI 1.06-1.54). CONCLUSION: Our study suggests a cumulative dosedependent increased risk of CM with the use of estrogens

Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines Marzagalli M., Casati L., Moretti R. M., Montagnani Marelli M. and Limonta P. PLoS One 10(7):e0134396 (2015) CONCLUSIONS: Our results demonstrate that ERβ is expressed in melanoma cell lines and that ERβ agonists differentially regulate the proliferation of these cells. These data confirm the notion that melanoma is a heterogeneous tumor and that genetic profiling is mandatory for the development of effective personalized therapeutic approaches for melanoma patients.

7.2.1.3 Cohort Studies Cohort studies are known to be less susceptible to biases than case-control studies and bring higher level of evidence. None of the cohort studies cited in the Opinion is adjusted for estrogen as a risk factor due to the study population: Veierod et al. 2003, 2010: 106,379 Norwegian and Swedish women Zhang et al. 2012: Nurses Health Study II, 73,494 female nurses Nielsen et al. 2012: 40,000 Swedish women

Other Confounding Factors not Assessed Role of melatonin Endocrine disruption Parabens in cosmetic products Role of human papilloma virus (HPV)

Human Papilloma Virus Found in 50% of Melanoma Biopsies

Important Host Factors, not Assessed Hormone receptor distribution / Gender MC1R receptor variants BRAF or N-RAS mutations TP53 protein expression level other oncogenes (e.g. CDK4, CCND1)

CMM: Various Histologic Growth Patterns Four histogenetic types of melanoma: superficial spreading, lentigo maligna, nodular, and acral lentiginous melanoma.

Some MC1R Variants are Independent of UV Exposure

Melanocortin 1 receptor variants and skin cancer risk Han J., Kraft P., Colditz G. A., Wong J. and Hunter D. J. International Journal of Cancer 119(8):1976-84 (2006) These findings indicated that the effects of the MC1R variants on skin cancer risk were independent from selfreported phenotypic pigmentation. Study population: Nurses Health Study, FEMALE

BRAF Mutations BRAF mutations are common only in melanomas arising in areas intermittently exposed to the sun BRAF mutations are rare in melanomas on skin that is chronically exposed to the sun

Distinct Sets of Genetic Alterations in Melanoma Curtin J. A., Fridlyand J., Kageshita T., Patel H. N., Busam K. J., Kutzner H., Cho K. -H., Aiba S., Bröcker E. -B., LeBoit P. E., Pinkel D. and Bastian B. C. New England Journal of Medicine 353(20):2135-47 (2005) The genetic alterations identified in melanomas at different sites and with different levels of sun exposure indicate that there are distinct genetic pathways in the development of melanoma and implicate CDK4 and CCND1 as independent oncogenes in melanomas without mutations in BRAF or N-RAS.

Distinct Sets of Genetic Alterations in Melanoma Curtin J. A., Fridlyand J., Kageshita T., Patel H. N., Busam K. J., Kutzner H., Cho K. -H., Aiba S., Bröcker E. -B., LeBoit P. E., Pinkel D. and Bastian B. C. New England Journal of Medicine 353(20):2135-47 (2005) Understanding whether the heterogeneity of melanoma with respect to the site, degree of exposure to the sun, and histologic characteristics is caused by biologically distinct types of melanoma is of great clinical importance, because it is likely to result in separate targeted therapeutic approaches and prevention strategies.

Open Questions Why do many melanomas appear in body sites without UV exposure? How can gender differences in body sites be explained? Why is low sun exposure a risk factor for melanoma? Which role plays the hormone receptor expression (e.g. estrogen) for the development of melanoma? Which roles play other confounding factors (e.g. for the development of melanoma)? How can uveal melanoma develop in a region with no UV?

Key Message, Part 2 Epidemiologic studies cited in the SCENIHR Opinion were not adjusted for some relevant host factors and confounding factors Therefore, conclusions drawn from these studies might be incorrect or misleading More studies are needed acknowledging the recent findings

THANK YOU! Epidemiologic studies cited in the SCENIHR Opinion were not adjusted for some relevant host factors and confounding factors Therefore, conclusions drawn from these studies might be incorrect or misleading More studies are needed acknowledging the recent findings